TY  - JOUR
AU  - Mallardo, Domenico
AU  - Woodford, Rachel
AU  - Menzies, Alexander M
AU  - Zimmer, Lisa
AU  - Williamson, Andrew
AU  - Ramelyte, Egle
AU  - Dimitriou, Florentia
AU  - Wicky, Alexandre
AU  - Wallace, Roslyn
AU  - Mallardo, Mario
AU  - Cortellini, Alessio
AU  - Budillon, Alfredo
AU  - Atkinson, Victoria
AU  - Sandhu, Shahneen
AU  - Olivier, Michielin
AU  - Dummer, Reinhard
AU  - Lorigan, Paul
AU  - Schadendorf, Dirk
AU  - Long, Georgina V
AU  - Simeone, Ester
AU  - Ascierto, Paolo A
TI  - The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
JO  - Journal of translational medicine
VL  - 21
IS  - 1
SN  - 1479-5876
CY  - London
PB  - BioMed Central
M1  - DKFZ-2023-02168
SP  - 753
PY  - 2023
AB  - The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue from patients with type 2 diabetes.To evaluate the impact of diabetes on oncological outcomes of patients with advanced melanoma treated with nivolumab plus the LAG3 inhibitor relatlimab we performed a retrospective multicenter study.Overall, 129 patients were included: 88 without diabetes before the treatment, 37 who were diagnosed with type 2 diabetes before the start of treatment, and 4 without diabetes before treatment who developed immune checkpoint inhibitor-induced diabetes (ICI-DM). PFS was 21.71 months (95
KW  - Diabetes (Other)
KW  - LDH (Other)
KW  - Melanoma (Other)
KW  - Nivolumab + relatlimab (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37880788
DO  - DOI:10.1186/s12967-023-04607-4
UR  - https://inrepo02.dkfz.de/record/284984
ER  -